INDIVIDUALISED CARE FROM EARLY RISK OF CARDIOVASCULAR DISEASE TO ESTABLISHED HEART FAILURE

从早期心血管疾病风险到确诊心力衰竭的个体化护理

• 批准号: 10088702
• 金额: $ 45.72万
• 依托单位: QUEEN'S UNIVERSITY OF BELFAST
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10088702
• 关键词: INDIVIDUALISED; CARE; EARLY; RISK; CARDIOVASCULAR

The burden of cardiovascular disease (CVD) on society is huge with >85 million people affected in Europe. The overall prevalence continues to grow due to unhealthy lifestyles and population aging. Heart failure (HF) is the final common pathway of all CVD and has a 5 year mortality rate of 20-50% despite significant advances in therapy. iCARE4CVD aims to address this burden by contributing to three essential steps to improve the current care pathways, covering all stages from early risk to established HF: 1) early diagnosis to identify patients at risk of CVD and divide them into clinically meaningful subgroups; 2) risk stratification for these subgroups to define the urgency for intervention; and 3) prediction of treatment response for each subgroup. This will be achieved by the following steps: clinical partners will provide a large set of cohorts including >1,000,000 patients with a wide range of biomarkers (e.g. digital, blood, imaging). Anonymous access to data will be enabled by using a blockchain-supported federated database. Artificial intelligence-based modeling also considering patient relevant factors will assess changes in risk and stratify patients according to their individual responses to therapy. Results will then be prospectively validated in new and ongoing large cohorts and a pilot trial to test the prediction of treatment response by using multiple biomarkers going beyond current risk prediction (such as SCORE) towards individualized therapy. Results will be used to provide novel decision tools for each step targeting newly identified subgroups and as a blueprint for innovative future trials to individualise prevention and therapy. Patient involvement is key in every part of iCARE4CVD (e.g. patient advisory board) to build a motivational framework for self-care by patients. The project brings together an EU-wide consortium with the needed resources and expertise from the public and private side to bring iCARE4CVD to success.

心血管疾病（CVD）对社会的负担是巨大的，在欧洲有超过8500万人受到影响。由于不健康的生活方式和人口老龄化，总体流行率继续上升。心力衰竭（HF）是所有CVD的最终共同途径，尽管治疗取得了显著进展，但其5年死亡率仍为20-50%。iCARE 4CVD旨在通过促进三个基本步骤来改善当前的护理途径来解决这一负担，涵盖从早期风险到确定HF的所有阶段：1）早期诊断，以识别具有CVD风险的患者并将其分为具有临床意义的亚组; 2）对这些亚组进行风险分层，以确定干预的紧迫性; 3）预测每个亚组的治疗反应。这将通过以下步骤实现：临床合作伙伴将提供一个大型队列集，包括> 1，000，000名具有广泛生物标志物（例如数字，血液，成像）的患者。匿名访问数据将通过使用区块链支持的联邦数据库来实现。基于人工智能的建模也考虑了患者相关因素，将评估风险变化，并根据患者对治疗的个体反应对患者进行分层。然后将在新的和正在进行的大型队列和一项试点试验中对结果进行前瞻性验证，以通过使用超出当前风险预测（如SCORE）的多种生物标志物来测试治疗反应的预测，以实现个性化治疗。结果将用于为针对新确定的亚组的每一步提供新的决策工具，并作为未来创新试验的蓝图，以个性化预防和治疗。患者参与是iCARE 4CVD每个部分（例如患者咨询委员会）的关键，以建立患者自我护理的激励框架。该项目汇集了一个欧盟范围的财团，拥有来自公共和私营部门的所需资源和专业知识，使iCARE 4CVD取得成功。